glp-1 drugs for parkinson's disease Are diabetes like Ozempic coming disease? — Parkinson Secrets GLP-1s are everywhere, but why?
Description
10.2337/db09-1694 2 ArmstrongM
In the 12 mg group, 18.2% of patients discontinued treatment due to adverse events
Abstract Diabetic Kidney Disease (DKD) is the leading cause of end stage renal disease (ESRD) worldwide
Klaff, R
Novel dual incretin agent, tirzepatide (LY3298176), for the treatment of type 2 diabetes mellitus and cardiometabolic health
2124 Collectively, these findings underscore the critical role of nutrient-mediated regulation of GLP-1, with implications for chronic lifestyle-associated diseases and overall metabolic health
